Cargando…

Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study

BACKGROUND AND AIM: We previously reported that vonoprazan-amoxicillin (VA) dual therapy for 7 or 10 days is not satisfactorily efficacious for Helicobacter pylori (H. pylori) eradication. We aimed to explore the efficacy of VA dual therapy for 14 days as a first-line treatment for H. pylori infecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yi, Xu, Xin, Liu, Xiao-Shun, He, Cong, Ouyang, Yao-Bin, Li, Nian-Shuang, Xie, Chuan, Peng, Chao, Zhu, Zhen-Hua, Xie, Yong, Shu, Xu, Zhu, Yin, Graham, David Y., Lu, Nong-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885262/ https://www.ncbi.nlm.nih.gov/pubmed/36726990 http://dx.doi.org/10.3389/fimmu.2022.1049908

Ejemplares similares

Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication
por: Hu, Yi, et al.
Publicado: (2022)

Efficacy of Vonoprazan for Helicobacter pylori Eradication
por: Kiyotoki, Shu, et al.
Publicado: (2019)

Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of Helicobacter pylori: A Non-Inferiority Clinical Trial
por: Li, Juan, et al.
Publicado: (2023)

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
por: Furuta, Takahisa, et al.
Publicado: (2023)

The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study
por: Lin, Yimin, et al.
Publicado: (2022)

Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Düzenli, Tolga, et al.
Publicado: (2023)

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori
por: Yang, Faming, et al.
Publicado: (2023)

Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis
por: Zhang, Wen-Lin, et al.
Publicado: (2023)

The efficacy and safety of vonoprazan–amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis
por: Feng, Jia-Hui, et al.
Publicado: (2023)

Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
por: Sugimoto, Mitsushige, et al.
Publicado: (2019)

RE: Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Vonoprazan and high‐dose amoxicillin dual therapy for Helicobacter pylori first‐line eradication: A single‐arm, interventional study
por: Sue, Soichiro, et al.
Publicado: (2022)

Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
por: Kusunoki, Maho, et al.
Publicado: (2019)

The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori
por: Zhang, Zinan, et al.
Publicado: (2023)

Vonoprazan-Associated Gastric Mucosal Redness in Non-Helicobacter pylori-Infected and Helicobacter pylori-Eradicated Stomach
por: Kubo, Kimitoshi, et al.
Publicado: (2021)

Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial
por: Zuberi, Bader Faiyaz, et al.
Publicado: (2022)

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
por: Sakurai, Kouichi, et al.
Publicado: (2017)

The impact of Helicobacter pylori eradication with vonoprazan-amoxicillin dual therapy combined with probiotics on oral microbiota: a randomized double-blind placebo-controlled trial
por: Peng, Ruolin, et al.
Publicado: (2023)

Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China
por: Gao, Wen, et al.
Publicado: (2022)

14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial
por: Yang, Qinyu, et al.
Publicado: (2023)

First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
por: Sue, Soichiro, et al.
Publicado: (2017)

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
por: Suzuki, Sho, et al.
Publicado: (2020)

Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant Helicobacter pylori
por: Sue, Soichiro, et al.
Publicado: (2023)

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
por: Tanabe, Hiroki, et al.
Publicado: (2018)

Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016)

Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Kashani, Negin, et al.
Publicado: (2018)

Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial
por: Mansour-Ghanaei, Fariborz, et al.
Publicado: (2019)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis
por: Liu, Ligang, et al.
Publicado: (2023)

Response to: Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Sue, Soichiro, et al.
Publicado: (2018)

Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2018)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial
por: Chen, Shasha, et al.
Publicado: (2023)

Levofloxacin-Amoxicillin/Clavulanate-Rabeprazole versus a Standard Seven-Day Triple Therapy for Eradication of Helicobacter pylori Infection
por: Chen, Ming-Cheh, et al.
Publicado: (2014)

The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy
por: Miftahussurur, Muhammad, et al.
Publicado: (2020)

Eradication of Helicobacter pylori in Children by Triple Therapy Regimens of Amoxicillin, Omeprazole, and Clarithromycin or Azithromycin
por: Esmaeili-Dooki, Mohammad Reza, et al.
Publicado: (2015)

Efficacy and safety of vonoprazan–amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial
por: Wang, Xiaolei, et al.
Publicado: (2023)

Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan
por: Suzuki, Sho, et al.
Publicado: (2023)

Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori
por: Saito, Yoshimasa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_il0e30vem8gqctdl1o3kn4no1n